Acorda gets a badly needed PDUFA date with the FDA on Parkinson's drug; Takeda signs neurological collaboration with antisense player Wave Life Sciences
→ Acorda $ACOR says that the FDA has finally accepted their application for Inbrija (CVT-301), putting their inhaled form of levodopa for Parkinson’s on track for a marketing decision by October 5. The regulatory advance comes 6 months after the agency initially refused to file their application, which now leaves the FDA due to make a decision by October. That’s a big deal at Acorda, as its last remaining patent protecting its big drug Ampyra is set to expire this summer, leaving them stripped of any legal armor against the generics that will shred that market. Acorda relies on Ampyra for almost all of its revenue.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
